NYXH Fundamental Analysis - NYXOAH SA

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to NYXH. NYXH was compared to 63 industry peers in the Health Care Equipment & Supplies industry. The financial health of NYXH is average, but there are quite some concerns on its profitability. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NYXH has reported negative net income.

In the past year NYXH has reported a negative cash flow from operations.

In the past 5 years NYXH always reported negative net income.

NYXH had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NYXH's Return On Assets of -66.28% is on the low side compared to the rest of the industry. NYXH is outperformed by 90.48% of its industry peers.

NYXH has a Return On Equity of -105.18%. This is amonst the worse of the industry: NYXH underperforms 82.54% of its industry peers.

		Industry Rank	Sector Rank
ROA	-66.28%
ROE	-105.18%
ROIC	N/A

ROA(3y)-31.19%

ROA(5y)-24.1%

ROE(3y)-40.78%

ROE(5y)-30.7%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NYXH has a Gross Margin of 65.27%. This is in the better half of the industry: NYXH outperforms 68.25% of its industry peers.

In the last couple of years the Gross Margin of NYXH has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	65.27%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.63%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NYXH has more shares outstanding

The number of shares outstanding for NYXH has been increased compared to 5 years ago.

The debt/assets ratio for NYXH is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.14, we must say that NYXH is in the distress zone and has some risk of bankruptcy.

NYXH's Altman-Z score of -2.14 is on the low side compared to the rest of the industry. NYXH is outperformed by 84.13% of its industry peers.

NYXH has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.

NYXH's Debt to Equity ratio of 0.29 is in line compared to the rest of the industry. NYXH outperforms 57.14% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.29
Debt/FCF	N/A
Altman-Z	-2.14

ROIC/WACCN/A

WACC7.32%

2.3 Liquidity

NYXH has a Current Ratio of 2.63. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.

NYXH has a better Current ratio (2.63) than 74.60% of its industry peers.

NYXH has a Quick Ratio of 2.38. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.38, NYXH belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.63
Quick Ratio	2.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NYXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.

NYXH shows a small growth in Revenue. In the last year, the Revenue has grown by 3.98%.

Measured over the past years, NYXH shows a very strong growth in Revenue. The Revenue has been growing by 74.42% on average per year.

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27.02%

Revenue 1Y (TTM)3.98%

Revenue growth 3Y74.42%

Revenue growth 5YN/A

Sales Q2Q%55.77%

3.2 Future

Based on estimates for the next years, NYXH will show a small growth in Earnings Per Share. The EPS will grow by 4.80% on average per year.

NYXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 117.81% yearly.

EPS Next Y-22.39%

EPS Next 2Y-7.4%

EPS Next 3Y4.8%

EPS Next 5YN/A

Revenue Next Year51.62%

Revenue Next 2Y145.37%

Revenue Next 3Y140.02%

Revenue Next 5Y117.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-7.4%

EPS Next 3Y4.8%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NYXH does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NYXOAH SA

EBR:NYXH (12/10/2025, 12:10:01 PM)

4.213

-0.03 (-0.64%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-13 2025-11-13/amc

Earnings (Next)03-11 2026-03-11/amc

Inst Owners17.62%

Inst Owner ChangeN/A

Ins Owners19.2%

Ins Owner ChangeN/A

Market Cap181.29M

Revenue(TTM)4.52M

Net Income(TTM)-77.20M

Analysts81.43

Price Target10.07 (139.02%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-8.5%

Min EPS beat(2)-22.16%

Max EPS beat(2)5.16%

EPS beat(4)2

Avg EPS beat(4)-4.61%

Min EPS beat(4)-22.16%

Max EPS beat(4)5.16%

EPS beat(8)6

Avg EPS beat(8)2.91%

EPS beat(12)7

Avg EPS beat(12)-7.28%

EPS beat(16)9

Avg EPS beat(16)-4.34%

Revenue beat(2)0

Avg Revenue beat(2)-19.91%

Min Revenue beat(2)-38.43%

Max Revenue beat(2)-1.4%

Revenue beat(4)0

Avg Revenue beat(4)-21.65%

Min Revenue beat(4)-38.43%

Max Revenue beat(4)-1.4%

Revenue beat(8)1

Avg Revenue beat(8)-22.06%

Revenue beat(12)1

Avg Revenue beat(12)-32.46%

Revenue beat(16)1

Avg Revenue beat(16)-37%

PT rev (1m)-17.36%

PT rev (3m)-22.24%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-0.57%

EPS NY rev (1m)1.96%

EPS NY rev (3m)-2.97%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)-3.43%

Revenue NY rev (3m)-26.71%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	36.75
P/FCF	N/A
P/OCF	N/A
P/B	2.47
P/tB	8.24
EV/EBITDA	N/A

EPS(TTM)-2.24

EYN/A

EPS(NY)-2.08

Fwd EYN/A

FCF(TTM)-1.45

FCFYN/A

OCF(TTM)-1.41

OCFYN/A

SpS0.11

BVpS1.71

TBVpS0.51

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-66.28%
ROE	-105.18%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	65.27%
FCFM	N/A

ROA(3y)-31.19%

ROA(5y)-24.1%

ROE(3y)-40.78%

ROE(5y)-30.7%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.63%

GM growth 5YN/A

F-Score3

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	0.29
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	49.33%
Cap/Sales	29.96%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.63
Quick Ratio	2.38
Altman-Z	-2.14

F-Score3

WACC7.32%

ROIC/WACCN/A

Cap/Depr(3y)64.88%

Cap/Depr(5y)74.74%

Cap/Sales(3y)37.33%

Cap/Sales(5y)219.78%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27.02%

EPS Next Y-22.39%

EPS Next 2Y-7.4%

EPS Next 3Y4.8%

EPS Next 5YN/A

Revenue 1Y (TTM)3.98%

Revenue growth 3Y74.42%

Revenue growth 5YN/A

Sales Q2Q%55.77%

Revenue Next Year51.62%

Revenue Next 2Y145.37%

Revenue Next 3Y140.02%

Revenue Next 5Y117.81%

EBIT growth 1Y-55.84%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-47.24%

EBIT Next 3Y-14.81%

EBIT Next 5Y11.04%

FCF growth 1Y-45.81%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-46.67%

OCF growth 3YN/A

OCF growth 5YN/A

NYXOAH SA / NYXH.BR FAQ

What is the fundamental rating for NYXH stock?

ChartMill assigns a fundamental rating of 3 / 10 to NYXH.BR.

What is the valuation status for NYXH stock?

ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH.BR). This can be considered as Overvalued.

Can you provide the profitability details for NYXOAH SA?

NYXOAH SA (NYXH.BR) has a profitability rating of 1 / 10.

NYXOAH SA (NYXH.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NYXOAH SA / NYXH.BR FAQ

What is the fundamental rating for NYXH stock?

What is the valuation status for NYXH stock?

Can you provide the profitability details for NYXOAH SA?